Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus...

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C virus (HCV) infection remains a significant global health concern.
• Interferon-based therapies have been a cornerstone of HCV treatment.
• Evaluating novel interferon formulations like consensus interferon (CIFN) is crucial for improving treatment outcomes.

Purpose of the Study:

• To compare the efficacy and safety of consensus interferon (CIFN) versus recombinant interferon alfa-2b (IFN-alpha2b) in patients with chronic hepatitis C.
• To assess the impact of different CIFN dosages (3 mcg and 9 mcg) on viral load and liver enzyme normalization.
• To evaluate treatment effects on HCV RNA levels, particularly in patients with HCV genotype 1.

Main Methods:

• A multicenter, randomized, controlled, double-blind, phase III study involving 704 patients.
• Patients received subcutaneous CIFN (3 mcg or 9 mcg) or IFN-alpha2b (15 mcg) three times weekly for 24 weeks.
• Efficacy endpoints included normalization of serum alanine transaminase (ALT) and undetectable HCV RNA by RT-PCR.

Main Results:

• The 9 mcg CIFN dose demonstrated a greater reduction in serum HCV RNA concentrations compared to 15 mcg IFN-alpha2b (P < .01).
• Patients with HCV genotype 1 showed significantly greater reduction in HCV RNA with 9 mcg CIFN.
• Sustained ALT normalization and undetectable HCV RNA rates were comparable between 9 mcg CIFN and 15 mcg IFN-alpha2b groups.

Conclusions:

• Administration of 9 mcg CIFN three times weekly for 6 months is safe and effective in reducing serum HCV RNA concentration.
• CIFN, particularly at the 9 mcg dose, offers a promising alternative for chronic hepatitis C treatment.
• Further research may explore CIFN's role in combination therapies for sustained viral clearance.